P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients With TP53 and KRAS Mutated Stage IV NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.620
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MA19.10 Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes With Chemo-Immunotherapy in Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P021 the Impact of TP53 Mutation and Tumor Mutation Number on Outcomes in Patients With Stage I Non Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Relationships Between KRAS Mutation Status and Baseline Radiographic Distribution of Disease in Patients With Stage IV Colorectal Cancer

Abdominal Imaging
2014English

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Impact of Unfavorable Factors on Outcomes Among Inoperable Stage II-IV Non–Small Cell Lung Cancer Patients Treated With Proton Therapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

P061 Real Clinical Practice of Using Immunotherapy in NSCLC Patients With EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 Years Old) With EGFR-mutated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated With First-Line Tyrosine Kinase Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy